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ABSTRACT
Introduction: Ranibizumab and aflibercept are
anti-vascular endothelial growth factor agents
licensed for the treatment of visual impairment
due to macular edema secondary to branch
retinal vein occlusion (BRVO). The aim of this
study was to estimate, from a UK healthcare
payer’s perspective, the cost-effectiveness of
ranibizumab versus aflibercept in this
indication.
Methods: A Markov model was used to simulate
the outcomes and costs of treating BRVO.
Patient baseline characteristics and efficacy
data for ranibizumab were obtained from the
BRAVO trial. The relative efficacy of aflibercept
was derived from a published network
meta-analysis. Injection frequencies were
derived from ranibizumab and aflibercept
studies included in the network meta-analysis.
Health states were defined by increments of
10 letters in best corrected visual acuity (BCVA).
Patients could gain or lose a maximum of two
health states between cycles. The first cycle was
6 months, followed by monthly cycles.
Different utility values were assigned to the
better-seeing and worse-seeing eyes based on
BCVA. A 2-year treatment time frame and a
lifetime time horizon were used. Future costs
and health outcomes were discounted at 3.5%
per annum. Sensitivity analyses were used to
test the robustness of the model.
Results: The lifetime cost per patient treated
was £15,273 with ranibizumab and £17,347
with aflibercept. Ranibizumab was dominant
over aflibercept, producing incremental health
gains of 0.0120 quality-adjusted life-years
(QALYs) and cost savings of £2074. Net
monetary benefit for ranibizumab at a
willingness-to-pay threshold of £20,000/QALY
was £2314. Sensitivity analyses showed that the
results were robust to variations in model
parameters.
Conclusions: Ranibizumab provides greater
health gains at a lower overall cost than
aflibercept in the treatment of visual
Electronic supplementary material The online
version of this article (doi:10.1007/s12325-015-0279-0)
contains supplementary material, which is available to
authorized users.
L. Adedokun (&)




Novartis Ireland Limited, Dublin, Ireland
Adv Ther (2016) 33:116–128
DOI 10.1007/s12325-015-0279-0
impairment due to macular edema secondary to
BRVO. Ranibizumab is therefore cost-effective
from a UK healthcare payer’s perspective.
Funding: Novartis Pharma AG, Basel,
Switzerland
Keywords: Aflibercept; Branch retinal vein
occlusion; Cost-effectiveness; Markov model;
Ophthalmology; Ranibizumab; Retina
INTRODUCTION
Retinal vein occlusion (RVO) occurs when a
thrombus obstructs a retinal vein [1] and is one
of the most common causes of visual loss in
older adults [2, 3]. In central RVO, the blockage
occurs in the main retinal vein at the optic
nerve; in branch RVO (BRVO), it occurs at an
arteriovenous crossing where an artery and vein
share a common vascular sheath. Retinal vein
thrombosis raises retinal capillary pressure,
which results in increased capillary
permeability. Increased levels of vascular
endothelial growth factor (VEGF) are triggered,
which augment vascular permeability and
proliferation of new vessels [1]. Macular
hemorrhage, edema, and ischemia can develop
and affect the severity of vision loss; of these,
macular edema is most frequently responsible,
and develops in 5–15% of eyes with BRVO [4].
The prevalence of BRVO has been estimated
to be 4.42 per 1000 persons, based on pooled
data from population-based studies in the USA,
Europe, Asia, and Australia [3]. In England and
Wales, approximately 11,600 people with BRVO
have visual impairment (VI) each year as a result
of macular edema [1]. Vision loss can impede
usual daily activities, resulting in dependency
on others and significant reductions in
health-related quality of life (HRQoL) [5].
Increased healthcare utilization and
expenditure, costly rehabilitation services, and
the need for caregiver time can increase the
socioeconomic burden of RVO [5, 6].
The treatments routinely used in the UK
National Health Service (NHS) for BRVO are
ranibizumab and grid laser photocoagulation. A
recent UK economic evaluation concluded that
ranibizumab was cost-effective relative to grid
laser photocoagulation [7].
Ranibizumab is a monoclonal anti-VEGF-A
antibody fragment licensed for the treatment of
VI due to macular edema secondary to RVO [8,
9]. Under its current EU label, a dose of 0.5 mg is
administered by intravitreal injection (IVI) once
per month until maximum visual acuity is
achieved and/or there are no signs of disease
activity. In patients with RVO, initially, three or
more consecutive monthly injections may be
needed. Thereafter, monitoring and treatment
intervals should be determined by the physician
and should be based on disease activity as
assessed by visual acuity and/or anatomical
parameters [9]. The use of ranibizumab in
BRVO has been evaluated in two pivotal trials:
BRAVO (ClinicalTrials.gov identifier,
NCT00486018) [10] and HORIZON
(ClinicalTrials.gov identifier, NCT01442064)
[11]. In BRAVO, ranibizumab 0.5 mg provided
a rapid and significant improvement in visual
acuity compared with sham injections [10];
patients in the ranibizumab group gained a
mean of 18.3 letters on the Early Treatment
Diabetic Retinopathy Study scale, compared
with 7.3 letters in the sham group
(P\0.0001). In addition, 61% of patients
receiving ranibizumab gained 15 letters or
more, compared with 29% receiving sham
injection (P\0.0001). Visual improvement
was maintained for the next 6 months
(through to month 12), during which
ranibizumab was given as required [12] and
maintained for a total of 24 months, as
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demonstrated in the 12-month HORIZON
open-label extension trial [11].
A second anti-VEGF agent, aflibercept (a fully
human recombinant fusion protein), is licensed
for the treatment of macular edema secondary
to RVO [13]. The phase 3 VIBRANT trial
(ClinicalTrials.gov identifier, NCT01521559)
showed that in patients with VI due to
macular edema secondary to BRVO, aflibercept
administered at a dose of 2.0 mg by IVI every
4 weeks provided greater visual improvement
than grid laser photocoagulation at 24 weeks
[14]: 53% of eyes treated with aflibercept gained
15 letters or more from baseline at week 24,
compared with 27% of those receiving laser
treatment (P = 0.0003). Eyes treated with
aflibercept gained an average of 17.0 letters,
compared with 6.9 letters when treated with
laser (P\0.0001).
Given the socioeconomic burden of VI
caused by BRVO, it is important to evaluate
the cost-effectiveness of therapies licensed for
this condition. At the time of this study, we are
unaware of UK economic evaluations in the
peer-reviewed literature comparing
ranibizumab with aflibercept in BRVO. The
objective of this study was to compare the
cost-effectiveness of ranibizumab with




This study was based on a Microsoft Excel
Markov model used in a submission to the
National Institute for Health and Care
Excellence (NICE) [15]. The model, which
simulated the health outcomes, utilities and
costs experienced by patients treated with
ranibizumab for macular edema secondary to
RVO, was adapted by including aflibercept as a
comparator. Internal calculations and settings
in the model were revised to accommodate the
new arm. The model was populated using data
from the BRAVO trial [10] and a published
network meta-analysis (NMA) [16]. It followed a
cohort of patients, whose baseline
characteristics were derived from the BRAVO
trial: their mean age was 67.5 years and 51% of
patients had a baseline best corrected visual
acuity (BCVA) of 56–75 letters (Table 1) [10].
Based on the proportion of patients whose
study eye was the better-seeing eye (BSE) or
worse-seeing eye (WSE) at baseline in the
BRAVO trial, it was assumed that 10% of
treatments would be in the patient’s BSE,
increasing to 21.5% at 12 months [7].
In the Markov model, patients cycled
between eight health states defined by BCVA
intervals ranging from \25 letters to
86–100 letters, and a ninth absorbing ‘death’
state (Fig. 1). The first cycle was 6 months, in
line with the published comparative
effectiveness data; monthly cycles were
applied thereafter. Patients could move up or
down a maximum of two health states within
Table 1 Baseline best corrected visual acuity in patients
included in the model
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each cycle over a lifetime time horizon.
A half-cycle correction was applied.
The timeframe for anti-VEGF treatments was
assumed to be 2 years. The first-year transition
probabilities (TPs) for the ranibizumab arm were
calculated using the full analysis set comprising
12-month data from the BRAVO trial [10, 12].
The treatment effect was assumed to be
maintained in the second year, in line with
the results of the HORIZON trial [11]. It was
assumed that patients did not receive any
treatment from year 3 onwards, and the
natural decline in BCVA was modeled based
on data from a population-based observational
study [17]. This enabled the calculation of a
0.031% monthly probability of losing
10–20 letters, as used in the NICE submission
[7, 15].
There are no published head-to-head trials
comparing the efficacy of ranibizumab and
aflibercept. The TPs for the aflibercept arm
were therefore calculated using the odds ratio
(OR) versus ranibizumab from a published NMA
[16]. The NMA was based on eight randomized
controlled trials involving 1743 adult patients
and included an assessment of the baseline
patient characteristics as well as adjustments for
different BCVA levels across the trials. The
results showed that there were numerical
differences in efficacy for ranibizumab versus
aflibercept for the proportion of patients
gaining 15 letters or more from baseline [OR
1.06; 95% credible interval (CrI) 0.16–8.94].
The OR from the NMA was assumed to apply
to a gain of 10 letters or more in the first
6-month cycle. In addition, the percentages of
patients losing 10 letters or more between two
cycles were assumed to be the same in the
ranibizumab and aflibercept arms. Following
the first cycle, the same TPs were assumed for
both arms, given the lack of comparative data.
Effectiveness was assumed to be constant across
all visual acuity levels. The TP calculations for
aflibercept are presented in Table S1 in the
supplementary material.
It was assumed that the rate of adverse events
for ranibizumab and aflibercept was the same,
consistent with the NICE assessment of
aflibercept in neovascular age-related macular
degeneration [18].
All-cause mortality was included in the
model using annual rates based on life
tables for England and Wales. In line with a
previous model in BRVO, it was assumed that
Definition of blindness: ≤ 35 letters
DEATH

















Fig. 1 Structure of the Markov model, showing health states and possible transitions between states. ETDRS Early
Treatment Diabetic Retinopathy Study
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worsening in BCVA was associated with
increased mortality. In the BSE, a risk ratio of
1 was applied to BCVA letter scores above 56,
1.23 for 36–55 letters, and 1.54 for below
36 letters. In the WSE, a risk ratio of 1.23 was
applied only for BCVA levels below 35 letters [7].
Utility Values
Utility values for each health state were
assigned based on BCVA and whether the
treated eye was the BSE or WSE. Utility values
for the BSE health states were obtained from a
recent cost-effectiveness evaluation in diabetic
macular edema (DME) [19]: the values, which
were calculated using data from Czoski-Murray
et al. [20], ranged from 0.850 for the best
possible state to 0.353 for the worst possible
state. For the WSE, due to the absence of
appropriate data, it was assumed that patients
could experience a maximum gain of 0.1 utility
between the best and worst states (compared
with 0.52 in the BSE). Table 2 shows the utility
values in the BSE according to BCVA.
Resource Use
The number of ranibizumab injections in the
first 6 months was based on a weighted mean of
the number of injections reported in
ranibizumab studies included in the NMA
[BRAVO, BRIGHTER (ClinicalTrials.gov
identifier, NCT01599650) and COMRADE-B
(ClinicalTrials.gov identifier, NCT01396057)]
[16]. A similar approach was used in an
economic model for DME submitted to NICE
[21]. The injection frequency for months 7–12
was obtained from the BRAVO trial [12].
Aflibercept injection frequencies for the first
year were obtained from the VIBRANT trial [14,
22]. For the second year, ranibizumab injection
frequency was obtained from the HORIZON
trial, after excluding patients who did not enter
the extension study [7, 11]. The same injection
frequency was assumed for aflibercept in year 2.
The assumption around the number of
monitoring visits was in line with the NICE
model [15] and was applied similarly to both
arms in years 1 and 2. Injection and monitoring
frequencies are summarized in Table 3.
Costs
The model estimated the cost-effectiveness of
ranibizumab and aflibercept treatment from the
perspective of the NHS. The costs used in this
analysis, and associated assumptions, are
summarized in Table 4. Drug prices for
ranibizumab and aflibercept were obtained
from the British National Formulary [23, 24].
The costs of treatment visits and monitoring
visits were derived from a previous analysis [19]
and were updated to 2014 costs using the
Hospital and Community Health Services
inflation index [25]. The cost of blindness was
associated with individuals whose BCVA was
less than 35 letters (see Table S2 in the
Table 2 Utility values used in the model, by BCVA level















BCVA best corrected visual acuity
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supplementary material). Future costs and
health outcomes were discounted at 3.5% per
annum.
Economic Analysis
The incremental cost-effectiveness ratio (ICER)
was calculated as the ratio of the mean
incremental cost and mean incremental
quality-adjusted life-years (QALYs) for
ranibizumab compared with aflibercept. Net
monetary benefit (NMB) was calculated
assuming the £20,000/QALY willingness-to-pay
threshold recommended by NICE [26]. The NMB
is equal to the incremental QALYs multiplied by
the willingness-to-pay threshold of £20,000
minus the incremental cost. A NMB greater than
£0 indicates that an intervention is beneficial at
Table 4 Key assumptions relating to treatment cost
Cost Data source for update Cost per item (£)
Administration visita Regnier et al. 2015 [19]b 169.84
Monitoring visita Regnier et al. 2015 [19]b 133.08
Ranibizumab BNF [23] 742.00 per treatment
Aﬂibercept BNF [23] 816.00 per treatment
BNF British National Formulary
a Applies to ranibizumab and aﬂibercept
b Costs updated to 2014 using Hospital and Community Health Services Pay and Prices Series 2013/14 [25]
Table 3 Key model inputs for the base case scenario
Ranibizumab Aﬂibercept
Year 1
BCVA data for TPs BRAVO [10] Network meta-analysis [16]






Injection frequency, months 7–12 2.7 (BRAVO [10]) 3.3 (VIBRANT [14])
Monitoring visits 3 (assumption) 3 (assumption: same as ranibizumab)
Year 2
BCVA data for TPs HORIZON [11] Assumption (same as ranibizumab)
Injection frequency 1.9 (HORIZON [7, 11]) 1.9 (assumption: same as ranibizumab)
Monitoring visits 4.1 (assumption) 4.1 (assumption: same as ranibizumab)
Model assumes the same adverse event rate for ranibizumab and aﬂibercept
BCVA best corrected visual acuity, TP transition probability
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the threshold; a higher NMB indicates greater
value. One-way sensitivity analyses were used to
explore uncertainty around key inputs to the
model and the effect on the resultant NMB was
calculated. A sensitivity analysis was conducted
on the impact of a price discount, as net drug
prices are not publicly available. Probabilistic
sensitivity analysis (PSA) was used to model joint
parameter uncertainty to assess the overall
uncertainty around the ICER. The probability
distributions chosen for the PSA were based on
those recommended for health economic
analysis [27], shown in Table S3 in the
supplementary material.
Compliance with Ethics Guidelines
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Base Case Scenario
Ranibizumab was associated with a QALY gain
over aflibercept of 0.0120 per patient (Table 5).
Lifetime costs per patient were lower with
ranibizumab (£15,273) than with aflibercept
(£17,347; difference of £2074). Ranibizumab
led to greater health gains at lower cost and
was therefore dominant over aflibercept. The
NMB was £2314 at a willingness-to-pay
threshold of £20,000/QALY.
Sensitivity Analyses
The one-way sensitivity analyses showed that
the model results were robust to variations in
key model parameters (Fig. 2). The parameter
that had the most impact was the OR for
ranibizumab versus aflibercept. Using the
lower end of the OR CrI (0.16), the NMB was
negative (-£1145), due to fewer QALYs in the
ranibizumab arm. In contrast, the NMB was
positive (£11,310) at the higher end of the CrI
(8.94), due to costs saved in the ranibizumab
arm. Ranibizumab provided a positive NMB
when a 15-year time horizon (£2239) and
1-year time horizon were assumed (£1587).
When the number of injections for
ranibizumab was assumed to be the same as
for aflibercept in years 1 and 2, ranibizumab
remained dominant (NMB of £1268).
Ranibizumab provided a positive NMB (£2609)
when the number of injections was assumed to
be 4.8 in the first 6 months, based on the
BRIGHTER trial [28] and similarly a NMB of
£1805 when 5.7 injections were used, based on
the BRAVO trial [10]. When similar efficacy was
assumed for ranibizumab and aflibercept (i.e.,
an OR of 1), there were incremental savings
associated with ranibizumab, with a NMB of
£1929. When the OR was applied only to the
proportion of patients gaining between 10 and
20 letters, the NMB was £2049. A NMB of £1436
was obtained when the price of aflibercept was
assumed to be the same as ranibizumab (£742).
When the price of aflibercept was assumed to be
20% lower than assumed in the base case (i.e.,
Table 5 Base case cost-effectiveness results, per patient
Comparison Total cost (£) Total QALYs Incremental cost (£) Incremental QALYs NMB (£)
Ranibizumab 15,273 9.668 -2074 0.0120 2314
Aﬂibercept 17,347 9.656
NMB net monetary beneﬁt, QALY quality-adjusted life-year
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£653 versus £742/dose for ranibizumab),
ranibizumab still provided a positive NMB
(£376). Results in favor of ranibizumab over
aflibercept were achieved when applying a
maximum of 0.3 utility gain in the WSE (NMB
of £2506), an approach consistent with the
NICE technology appraisal of ranibizumab in
the treatment of macular edema caused by RVO
[15].
The PSA showed that ranibizumab had a
62.7% probability of being cost-effective at a
willingness-to-pay threshold of £20,000/QALY
(Fig. 3). The cost-effectiveness acceptability
curve (Fig. 4) is relatively flat due to a high
–2000 20000 4000 6000 8000 12,00010,000
Ranibizumab vs aflibercept OR (0.16–8.94)
Equivalent injection frequency for aflibercept and ranibizumab
Aflibercept price (–20%–0%)
Time horizon (1 year–lifetime)
Equivalent price for aflibercept and ranibizumab
Ranibizumab injection frequency in the first 6 months
(4.8–5.7)
Maximum utility gain between worst and best states in the WSE
(0.1–0.3)
Efficacy OR (1–1.06)
Time horizon (15 years–lifetime)
Efficacy OR of 1.06 (≥ 10 and < 20 letters) and 1 (> 20 letters)
NMB (£)
Fig. 2 Tornado plots of one-way sensitivity analyses for ranibizumab compared with aﬂibercept. The range for the
ranibizumab versus aﬂibercept OR analysis is the 95% credible interval. The NMB in the base case scenario for ranibizumab






















Fig. 3 Scatter plot for probabilistic sensitivity analysis showing cost-effectiveness of ranibizumab compared with
aﬂibercept. QALY quality-adjusted life-year
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proportion of simulations located in the
bottom-right quadrant and upper-left
quadrants; neither of these quadrants is
affected by the cost-effectiveness threshold.
DISCUSSION
Our analyses showed that, from a UK healthcare
payer’s perspective, ranibizumab was dominant
over aflibercept because of lower lifetime costs
and higher QALY gains. The results were
demonstrated to be robust by a number of
one-way sensitivity analyses.
The OR from the NMA showed differences in
the efficacy of ranibizumab and aflibercept,
resulting in a higher probability of gaining
10 letters or more in BCVA with ranibizumab
in the model. The wide CrI around the OR
estimate was reflected in the PSA analysis,
which showed that simulations were spread
across the upper-left and bottom-right
quadrants.
The main drivers of the results were the
greater number of injections required and the
costs of injections associated with aflibercept.
Injection frequencies for ranibizumab and
aflibercept in the base case scenario were taken
from clinical trials, as these are the most robust
estimates available, in line with approaches
used in previous ranibizumab and aflibercept
models [15, 29]. This is in contrast to a recent
BRVO cost-effectiveness analysis submitted to
the Scottish Medicines Consortium in which
the treatment frequencies were assumed to be
similar for ranibizumab and aflibercept [22].
Taking this into consideration, a sensitivity
analysis in which the injection frequencies
were assumed to be similar for the two drugs
was run. Ranibizumab remained cost-effective
because of lower drug costs and because fewer
patients were in the low vision state (\35 letters
BCVA) where they incur costs associated with
blindness.
It should be noted that list drug prices were
used in the base case analysis; however, NHS
discounts and patient access schemes are in
place for both drugs, meaning that net drug
prices will be lower. A sensitivity analysis
showed that ranibizumab was cost saving
compared with aflibercept if the list price of
aflibercept was assumed to be the same as the
list price of ranibizumab. These results held
when a 20% discount was applied to the list



























ICER  threshold (£)
Fig. 4 Cost-effectiveness acceptability curve for ranibizumab. ICER incremental cost-effectiveness ratio
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UK decision maker, the net prices should be
considered in the context of this analysis as a
key driver of real-world cost-effectiveness.
The modeling approach used in the study is
valuable in that it allows a decision maker to
combine evidence from a variety of sources to
derive a single assessment of the impact of the
intervention on HRQoL, survival and overall
treatment costs. The model was built to allow a
variety of scenarios to be assessed, based on
various inputs and assumptions. This is
important as RVO is a complex disease, with
uncertainty around the factors that should be
accounted for within an assessment of the
treatment pathway and the measurements that
should be used. The study is of interest to UK
healthcare decision makers as both treatments
in the study are clinically relevant in the UK.
This cost-effectiveness analysis used UK-specific
data when available; this included mortality
data from life tables for England and Wales,
utilities derived from a UK population and cost
data from UK sources such as the British
National Formulary and NHS reference costs.
A limitation of the analysis is the structural
application of the OR data. The OR, which is
based on a gain of 15 letters or more, was
applied to health states based on 10-letter or
20-letter gains. This could lead to an
overestimation of the proportion of patients
gaining 20 or more letters in the aflibercept arm
of the model. The impact of the possible
overestimation of effectiveness was addressed
in the sensitivity analysis where the OR of 1.06
was conservatively applied only to the
aflibercept TPs of gaining between 10 and
20 letters. Ranibizumab remained dominant in
this analysis.
Another limitation is the lack of comparative
efficacy data between ranibizumab and
aflibercept beyond 6 months. Data from the
VIBRANT trial showed that the BCVA gains
observed in the first 6 months while on
aflibercept were maintained at the end of year
one [30]. This sustained treatment effect is also
observed in the BRAVO trial [12]. The present
analysis was therefore based on a conservative
assumption that both treatments had
equivalent efficacy after 6 months, and
explored the impact of different time horizons
on the results. Similarly, the rate of adverse
events with ranibizumab and aflibercept was
assumed to be the same. This assumption has
been used in another model [19] and is
supported by a systematic review of the
efficacy and safety of ranibizumab, aflibercept
and bevacizumab in neovascular age-related
macular degeneration, which reported a
similar frequency of severe adverse events for
all three drugs [31].
The analysis did not include bevacizumab,
a full-length anti-VEGF-A antibody developed
for the treatment of cancer; bevacizumab is
not licensed for the treatment of VI due to
macular edema secondary to BRVO. The
analysis did not compare ranibizumab with
grid laser photocoagulation therapy as this
has been assessed in a recent economic model
which demonstrated that ranibizumab was
more cost-effective [7]. The conclusions of
the authors regarding the costs and health
benefits of ranibizumab are in line with those
of the present study; the main differences
relate to the use of updated modeling
approaches, as well as updated cost, utility
and mortality data.
CONCLUSIONS
In this economic analysis from a UK healthcare
payer’s perspective, ranibizumab was dominant
over aflibercept for the treatment of macular
edema secondary to BRVO, resulting in lower
lifetime costs and higher QALY gains. Such
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evidence is valuable for formulary decision
making in the UK NHS and suggests that
ranibizumab should be used as the standard of
care for BRVO.
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